Martha Demski
Direktor/Vorstandsmitglied bei CHIMERIX, INC.
Vermögen: 107 277 $ am 30.04.2024
Profil
Martha J.
Demski is currently an Independent Director at Alpha Teknova, Inc., Lead Independent Director at Chimerix, Inc., and Independent Director at Equillium, Inc. She previously served as an Independent Director at ADMA Biologics, Inc., Adamas Pharmaceuticals LLC, Neothetics, Inc., and Bank of America Corp.
She was also the Chief Financial Officer & Senior Vice President at Ajinomoto Althea, Inc., Chief Operating & Financial Officer at Sidney Kimmel Cancer Center, and Senior Vice President at US Trust.
Ms. Demski's early career includes being the Chief Financial Officer & Vice President at Vical, Inc. She holds an undergraduate degree from Michigan State University and an MBA from The University of Chicago Booth School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CHIMERIX, INC.
0,08% | 31.03.2024 | 72 055 ( 0,08% ) | 64 201 $ | 30.04.2024 |
EQUILLIUM, INC.
0,07% | 22.05.2024 | 23 799 ( 0,07% ) | 43 076 $ | 30.04.2024 |
Aktive Positionen von Martha Demski
| Unternehmen | Position | Beginn |
|---|---|---|
| CHIMERIX, INC. | Direktor/Vorstandsmitglied | 01.08.2023 |
| EQUILLIUM, INC. | Direktor/Vorstandsmitglied | 01.09.2018 |
| ALPHA TEKNOVA, INC. | Direktor/Vorstandsmitglied | 31.08.2023 |
Ehemalige bekannte Positionen von Martha Demski
| Unternehmen | Position | Ende |
|---|---|---|
| ADMA BIOLOGICS, INC. | Direktor/Vorstandsmitglied | 06.06.2023 |
| ADAMAS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 24.11.2021 |
Neothetics, Inc.
 Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2018 |
Ajinomoto Althea, Inc.
 Ajinomoto Althea, Inc. Medical SpecialtiesHealth Technology Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA. | Finanzdirektor/CFO | 01.05.2017 |
Sidney Kimmel Cancer Center
 Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Finanzdirektor/CFO | 01.12.2010 |
Ausbildung von Martha Demski
| Michigan State University | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| CHIMERIX, INC. | Health Technology |
| ADMA BIOLOGICS, INC. | Health Technology |
| ALPHA TEKNOVA, INC. | Health Technology |
| EQUILLIUM, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc. Medical SpecialtiesHealth Technology Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA. | Health Technology |
Sidney Kimmel Cancer Center
Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Health Services |
| US Trust | Finance |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Health Technology |
